Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%


Sezer A., Gogishvili M., Bentsion D., Kilickap S., Lowczak A., Gumus M., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.14, 2019 (SCI İndekslerine Giren Dergi) identifier